Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
B 247 , 155161 (1992)
Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B
JW Pharmaceutical announced Wednesday that it has signed a license-in agreement with Chinese pharmaceutical company Gan & Lee Pharmaceuticals for the metabolic disease treatment "Bofanglutide (GZR18)." Through this agreement, JW Pharmaceutical has secured exclusive rights for domestic commercialization of the drug
By simultaneously activating the GLP-1 and GIP (glucose-dependent insulinotropic peptide) receptors, tirzepatide helps promote satiety, reduce food intake, and improve glycemic control, making it an effective option for individuals struggling with obesity and related metabolic disorders
